Sackler-Owned Mundipharma’s Sale of China Unit Said to Stall
- Auction on hold after bids fail to match price expectactions
- Offers were cut to reflect impact of issues such as Covid-19
This article is for subscribers only.
The plan by members of the billionaire Sackler family to sell the China assets of global pharmaceutical company Mundipharma International Ltd. for more than $1 billion has stalled over valuation, people familiar with the matter said.
A sale process run by Deutsche Bank AG has been put on hold after bids from both private equity firms and industry players failed to match the owner’s price expectations, the people said, asking not to be identified because the matter is private.
Have a confidential tip for our reporters? Get in Touch
Before it’s here, it’s on the Bloomberg Terminal
LEARN MORE
Up Next
Sackler-Owned Mundipharma’s Sale of China Unit Said to Stall